Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102139 | 1.00 | AAK1 (0.44) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL18215087 | 0.97 | AAK1 (0.44) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL28650981 | 0.97 | AAK1 (0.44) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL18215143 | 0.97 | AAK1 (0.44) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL6360143 | 0.92 | DPP4 (0.43) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL6360147 | 0.92 | DPP4 (0.43) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL6360141 | 0.92 | DPP4 (0.43) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL6360139 | 0.92 | DPP4 (0.43) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL12463556 | 0.91 | EPHX1 (0.45) | AAK1CTSLCA1CA2CTSK | |
| SCHEMBL22501529 | 0.91 | EPHX1 (0.45) | AAK1CTSLCA1CA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | AAK1 1591/4885CTSL 4188/4885CA1 1304/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | AAK1 1591/4885CTSL 4188/4885CA1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.